Thoracic Neoplasms Clinical Trial
Official title:
Prospect Study to Evaluate Clinical, Dosimetrical, Functional, Biological and Genetic Factors in Predicting Chemo-Radiotherapy Induced Lung and Esophagus Injury
The purpose of this study is to evaluate clinical, dosimetrical, functional, biological and genetic factors in predicting chemo-radiotherapy induced lung and esophagus injury.
We propose a prospective study to investigate the combinational effect of radiotherapeutic
dosimetric parameters [mean lung dose and percentage of lung volume receiving at least XGy
(Vx)] and biological parameters
[interleukin-1α(IL1α),interleukin-1β(IL1β),interleukin-6(IL6),interleukin-7(IL7),transforming growth factor beta (TGFB)] and manganese superoxide dismutase(MnSOD) in predicting radiation pneumonitis, fibrosis, and radiation esophageal injury. Eligibility included pathological or cytological proven thoracic cancer,ECOG performance status [PS] 0-2, no prior thoracic RT or chemotherapy,no distant metastasis and signed informed consent prior to study entry.
Basic pre-treatment information will be collected, which included ECOG PS, UICC/AJCC
stage,primary lesion site, history of smoking/coexisting lung disease/surgical resection,
and pulmonary function test of FEV1/VC/DLCO. Computed tomography [CT] of the whole lung in
treatment position. Blood test of IL1α,IL1β,IL6,IL7,TGFB and MnSOD by ELISA will be done
before and weekly during RT. RT must be given by photon energies >=6MV. Radiation lung and
esophageal injury will be assessed according to common toxicity criteria adverse effect
version3.0 [CTCAE-3.0] during RT and in every follow up visits. Genomic DNA is obtained from
the blood drawn during RT. Chi-square test, T test, analysis of variance, logistic
regression, and proportional hazard ratio method will be used to investigate whether the
parameter(s) can be effective in predicting radiation related sequelae.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Completed |
NCT02909452 -
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04741958 -
Role of Ultrasound Guided Peripheral Thoracic Tumors
|
N/A | |
Recruiting |
NCT04556344 -
Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer
|
N/A | |
Terminated |
NCT03306693 -
Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers
|
N/A | |
Completed |
NCT04751552 -
Erector Spinae Block for Thoracoscopic Surgery
|
N/A | |
Not yet recruiting |
NCT06104774 -
The Effects of a Family-Centered Tai Chi Exercise on Lung Function and Mental Health of Patients After Thoracoscopic Surgery
|
N/A | |
Completed |
NCT05770869 -
mHealth ALIBIRD: A Digital Health Care Model
|
N/A | |
Active, not recruiting |
NCT04589247 -
Improving Cancer Symptom Management
|
||
Not yet recruiting |
NCT04133337 -
Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
|
Phase 1/Phase 2 | |
Terminated |
NCT04644315 -
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
|
Phase 2 | |
Completed |
NCT02188563 -
A Comprehensive Smoking Cessation Intervention Duration Radiation for Upper Aerodigestive Cancers
|
N/A | |
Completed |
NCT03134872 -
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
|
Phase 3 | |
Not yet recruiting |
NCT04371796 -
Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
|
Phase 2 | |
Completed |
NCT00437372 -
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
|
Phase 1 | |
Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04862780 -
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT04776447 -
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
|
Phase 2 | |
Recruiting |
NCT05988736 -
Comparison Between McGrath and Macintosh Laryngoscopes for DLT Intubation in Thoracic Surgery Patients.
|
N/A | |
Not yet recruiting |
NCT06376084 -
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
|